Linker Information

General Information of This Linker
Linker ID
LIN0RXDPE
Linker Name
30kmPEG-Lys (PEG2 - Mal)-3 (Val-Cit-PAB-DEA)
Linker Type
Unclear
Antibody-Linker Relation
Unclear
Structure
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
CN117337196A Compound88 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio
10-40 %
Positive HER2 expression (HER2+++/++)
Method Description
Her2-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3000 cells/well and treated with the compound 88 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model Pancreatic ductal adenocarcinoma BxPC-3 cells CVCL_0186
CN117337196A Compound89 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 9 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 20% Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model Lung large cell carcinoma NCI-H661 cells CVCL_1577
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 22% Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model Lung squamous cell carcinoma NCI-H520 cells CVCL_1566
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 25% Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 10 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model Pancreatic ductal adenocarcinoma BxPC-3 cells CVCL_0186
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 35% Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model Pancreatic ductal adenocarcinoma BxPC-3 cells CVCL_0186
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 40% Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model Lung large cell carcinoma NCI-H661 cells CVCL_1577
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 42% Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 20 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model Lung squamous cell carcinoma NCI-H520 cells CVCL_1566
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 65% Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description
CD47/PD-L1-positive tumor cell line NCI-H520 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model Lung squamous cell carcinoma NCI-H520 cells CVCL_1566
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 70% Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description
CD47/PD-L1-positive tumor cell line NCI-H661 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model Lung large cell carcinoma NCI-H661 cells CVCL_1577
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Cell growth inhibition ratio ≈ 75% Positive CD47/PD-L1 expression (CD47/PD-L1+++/++)
Method Description
CD47/PD-L1-positive tumor cell line BXPC-3 cells were selected to be inoculated into 96-well plates with 3x105 cells/well and treated with the compound 89 with a dose of 40 ug/mL. Cell viability was measured by Cell Counting Kit-8 (CCK-8), and cell proliferation inhibition rate was calculated
In Vitro Model Pancreatic ductal adenocarcinoma BxPC-3 cells CVCL_0186
References
Ref 1 PEGylated antibody hydroxyl-bearing drug conjugates